Reproducibility of human papillomavirus detection using the Roche cobas®4800 real-time PCR, Hybrid Capture 2, Gen-Probe APTIMA and Genomica CLART assays. Implications for molecular cervical cancer screening

被引：0

作者：

Preisler, S. ^{[1
,2
]}

Rebolj, M. ^{[3
]}

Untermann, A. ^{[1
,2
]}

Ejegod, Moller D. ^{[1
,2
]}

Lynge, E. ^{[3
]}

Rygaard, C. ^{[1
]}

Bonde, J. ^{[1
,2
]}

机构：

[1] Copenhagen Univ Hosp, Dept Pathol, Hvidovre, Denmark

[2] Copenhagen Univ Hosp, Clin Res Ctr, Hvidovre, Denmark

[3] Univ Copenhagen, Dept Publ Hlth, Copenhagen, Denmark

来源：

APMIS | 2012年 / 120卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：27 / 27

页数：1

共 7 条

[1] Reproducibility of Human Papillomavirus detection using the Roche cobas HPV Test, QIAGEN Hybrid Capture 2, Gen-Probe APTIMA, and Genomica CLART assays; Implications for molecular cervical screening
Ejegod, D. M.
Preisler, S.
Rebolj, M.
Untermann, A.
Lynge, E.
Rygaard, C.
Bonde, J.
APMIS, 2013, 121 : 18 - 18
[2] Population based prevalence of human papillomavirus in > 5000 unselected, consecutive cervical SurePath® samples evaluated by Roche cobas®HPV real-time PCR, Qiagen Hybrid Capture 2®, Gen-Probe APTIMA® and Genomica CLART® assays: Implications for molecular cervical cancer screening
Preisler, S.
Rebolj, M.
Untermann, A.
Ejegod, D. M.
Lynge, E.
Rygaard, C.
Bonde, J.
APMIS, 2012, 120 : 23 - 24
[3] Reproducibility of human papilloma virus detection using the Roche COBAS 4800 real-time PCR platform: Implications for molecular cervical cancer screening
Untermann, A.
Asmussen, L.
Brink, Hansen M.
Rebolj, M.
Lynge, E.
Rygaard, C.
Bonde, J.
APMIS, 2011, 119 : 18 - 18
[4] Disagreement between Human Papillomavirus assays in primary cervical screening: Hybrid Capture 2, cobas, CLART, and APTIMA
Rebolj, M.
Preisler, S.
Ejegod, D. M.
Untermann, A.
Rygaard, C.
Lynge, E.
Bonde, J.
APMIS, 2013, 121 : 3 - 3
[5] Cross reactivity of Roche cobas®HPV test, Qiagen Hybrid Capture 2, and Gen-Probe APTIMA with non-oncogenic human papillomavirus types. Implications for molecular cervical cancer screening
Ejegod, D. M.
Preisler, S.
Rebolj, M.
Untermann, A.
Lynge, E.
Rygaard, C.
Bonde, J.
APMIS, 2012, 120 : 26 - 27
[6] Cross reactivity of Roche cobas® HPV test, Qiagen Hybrid Capture 2®, and Gen-Probe APTIMA® with non-oncogenic human papillomavirus types; Implications for molecular cervical cancer
Ejegod, D. M.
Preisler, S.
Rebolj, M.
Untermann, A.
Lynge, E.
Rygaard, C.
Bonde, J.
APMIS, 2013, 121 : 2 - 2
[7] Clinical Validation of a Type-Specific Real-Time Quantitative Human Papillomavirus PCR against the Performance of Hybrid Capture 2 for the Purpose of Cervical Cancer Screening
Depuydt, C. E.
Benoy, I. H.
Beert, J. F. A.
Criel, A. M.
Bogers, J. J.
Arbyn, M.
JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (12) : 4073 - 4077

← 1 →